CD8A and melanoma: In the B16 murine melanoma model, effector CD8+ T cells and activated NK cells cooperated and improved an immunotherapeutic response after treatment with interleukin‐2 (IL‐2) and cytotoxic T‐lymphocyte‐associated protein‐4 (CTLA‐4) blockade.